Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
Leuk Res. 2011 Apr;35(4):551-9. doi: 10.1016/j.leukres.2010.08.008. Epub 2010 Sep 9.
Myeloma is characterized by the overproduction and secretion of monoclonal protein. Inhibitors of the isoprenoid biosynthetic pathway (IBP) have pleiotropic effects in myeloma cells. To investigate whether IBP inhibition interferes with monoclonal protein secretion, human myeloma cells were treated with specific inhibitors of the IBP or prenyltransferases. These studies demonstrate that agents that inhibit Rab geranylgeranylation disrupt light chain trafficking, lead to accumulation of light chain in the endoplasmic reticulum, activate the unfolded protein response pathway and induce apoptosis. These studies provide a novel mechanism of action for IBP inhibitors and suggest that further exploration of Rab-targeted agents in myeloma is warranted.
骨髓瘤的特征是单克隆蛋白的过度产生和分泌。异戊烯生物合成途径(IBP)的抑制剂在骨髓瘤细胞中有多种作用。为了研究 IBP 抑制是否干扰单克隆蛋白的分泌,用 IBP 或prenyltransferase 的特异性抑制剂处理人骨髓瘤细胞。这些研究表明,抑制 Rab 异戊二烯基化的试剂会破坏轻链的运输,导致轻链在内质网中积累,激活未折叠蛋白反应途径并诱导细胞凋亡。这些研究为 IBP 抑制剂提供了一种新的作用机制,并表明进一步探索骨髓瘤中 Rab 靶向药物是合理的。